TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33737331

Group type: EXPERIMENTAL
Intervention: Visitor guidelines allowing parental visitation restricted to 1 parent
Number of subjects: 239

Group type: COMPARATOR
Intervention: Visitor guidelines not changed since initial review
Number of subjects: 239
Study: 34971795

Group type: EXPERIMENTAL
Intervention: Health‐4‐Families intervention (16-week distance-based intervention)
Number of subjects: 206
Study: 32112181

Group type: EXPERIMENTAL
Intervention: Amlodipine + Clomiphene Citrate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo + Clomiphene Citrate
Number of subjects: 124
Study: 36883163

Group type: EXPERIMENTAL
Intervention: Playing the puzzle game
Number of subjects: 44

Group type: COMPARATOR
Intervention: Watching (control group)
Number of subjects: 44
Study: 33637409

Group type: EXPERIMENTAL
Intervention: Tablet computer game (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard departmental preparation (n = 30)
Number of subjects: 60
Study: 32304015

Group type: EXPERIMENTAL
Intervention: Gilteritinib (dose range 20-450 mg, once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with itraconazole (CYP3A4 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with rifampicin (CYP3A inducer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with midazolam (CYP3A4 substrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gilteritinib coadministered with cephalexin (multidrug and toxin extrusion 1 substrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gilteritinib in subjects with hepatic impairment
Number of subjects: 0
Study: 36307315

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHMs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34649534

Group type: EXPERIMENTAL
Intervention: Interpersonal Counselling (IPC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: perinatal specific cognitive behavioural therapy (CBT)
Number of subjects: 52
Study: 32443364

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program using smart wearable device for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Self-exercise program as normal for 6 weeks
Number of subjects: 40
Study: 36177651

Group type: EXPERIMENTAL
Intervention: T2D diagnosed <50 years
Number of subjects: 25141

Group type: EXPERIMENTAL
Intervention: T1D
Number of subjects: 25141
Study: 34660501

Group type: EXPERIMENTAL
Intervention: Free oral HIV self-test kits (HIVST) offered to participants
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Free oral HIV self-test kits (HIVST)
Number of subjects: 305
Study: 32195955

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple facemask
Number of subjects: 0
Study: 35817957

Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d for 2 years, then 850 mg/d for 2 years)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 30
Study: 34029880

Group type: EXPERIMENTAL
Intervention: Online psychosocial intervention adjunctive to an activity monitor (Fitbit)
Number of subjects: 0
Study: 35395953

Group type: EXPERIMENTAL
Intervention: Personalized and home-based speech therapy for 8 weeks
Number of subjects: 215

Group type: COMPARATOR
Intervention: No intervention (waiting list control)
Number of subjects: 215
Study: 33522977

Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-based protocol (TIBP)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Transdiagnostic internet-based protocol with positive affect component (TIBP+PA)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Waiting list (WL) control group
Number of subjects: 216
Study: 32333541

Group type: EXPERIMENTAL
Intervention: Acupuncture (Jingjin needling)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication (Prednisone acetate, Acyclovir, Vitamin B12, Vitamin B1)
Number of subjects: 80
Study: 35435470

Group type: EXPERIMENTAL
Intervention: Knotless PEEK anchors
Number of subjects: 78

Group type: COMPARATOR
Intervention: Biodegradable anchors
Number of subjects: 78
Study: 34028112

Group type: EXPERIMENTAL
Intervention: TightRail™ mechanical rotating dilator sheath
Number of subjects: 372

Group type: COMPARATOR
Intervention: Excimer laser sheaths
Number of subjects: 372

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 372
Study: 32776425

Group type: EXPERIMENTAL
Intervention: Matched unrelated donor bone marrow transplantation (MUD BMT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Immune suppression therapy (IST)
Number of subjects: 23
Study: 36306548

Group type: EXPERIMENTAL
Intervention: Tele-coaching (TC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 14
Study: 33634446

Group type: EXPERIMENTAL
Intervention: Restarted anticoagulation within 14 days
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Restarted anticoagulation
Number of subjects: 352

Group type: COMPARATOR
Intervention: Not restarted anticoagulation
Number of subjects: 352
Study: 34883037

Group type: EXPERIMENTAL
Intervention: Tailored therapy (TT)
Number of subjects: 282

Group type: COMPARATOR
Intervention: PAM-B therapy
Number of subjects: 282
Study: 34700258

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy to Prevent Suicide (MBCT-S)
Number of subjects: 135

Group type: COMPARATOR
Intervention: enhanced treatment as usual (eTAU)
Number of subjects: 135
Study: 36216700

Group type: EXPERIMENTAL
Intervention: CTCA with selective FFRCT
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Standard clinical pathways
Number of subjects: 1399
Study: 34000949

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (BTX-A) infiltration (100 UI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physiologic serum infiltration (placebo)
Number of subjects: 16
Study: 32912276

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 300
Study: 34877858

Group type: EXPERIMENTAL
Intervention: Topical 0.3% amphotericin B in 30% dimethyl sulfoxide cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30% dimethyl sulfoxide cream (vehicle cream)
Number of subjects: 20
Study: 33504338

Group type: EXPERIMENTAL
Intervention: Mis-implementation of chronic disease programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organizational factors influencing mis-implementation
Number of subjects: 0
Study: 34270689

Group type: EXPERIMENTAL
Intervention: 400 g of intrusive force per segment (40 g per root)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 200 g of intrusive force per segment (20 g per root)
Number of subjects: 20
Study: 32734413

Group type: EXPERIMENTAL
Intervention: Educational video on LARC methods (7-minute duration)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Non-video group (control)
Number of subjects: 270
Study: 35134185

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine as postexposure prophylaxis
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Exposure to 2 suspected index cases
Number of subjects: 689

Group type: COMPARATOR
Intervention: County incidence
Number of subjects: 689
Study: 33227361

Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (wGRS)
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Ln-transformed Matsuda index
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: HOMA2-IR
Number of subjects: 1938
Study: 33164956

Group type: EXPERIMENTAL
Intervention: Dynamic core-postural chain stabilization (DCS) exercises
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT) exercises
Number of subjects: 31
Study: 37286262

Group type: EXPERIMENTAL
Intervention: Hemodynamic-guided HF management
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study: 36106642

Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 32450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32450
Study: 32533875

Group type: EXPERIMENTAL
Intervention: Shared oral care intervention
Number of subjects: 41
Study: 36150974

Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 606

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 606
Study: 32949780

Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive TMS (rTMS) synchronized to the positive peak of the sensorimotor μ-oscillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive TMS (rTMS) synchronized to the negative peak of the sensorimotor μ-oscillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 Hz repetitive TMS (rTMS) at random phase (control)
Number of subjects: 0
Study: 36285573

Group type: EXPERIMENTAL
Intervention: Standard bolus
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Split bolus 70/30 with 20% increment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Split bolus 60/40 with 20% increment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Split bolus 50/50 with 20% increment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Split bolus 50/50
Number of subjects: 25

Group type: COMPARATOR
Intervention: Split bolus 70/30
Number of subjects: 25
Study: 34503682

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-2 treatment in T-cell-deficient mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic ablation of ILC2
Number of subjects: 0
Study: 35781083

Group type: EXPERIMENTAL
Intervention: Reversed total shoulder arthroplasty (RTSA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 124
Study: 34105231

Group type: EXPERIMENTAL
Intervention: Ridge splitting with simultaneous implant placement using patient specific guides (PSGs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional technique (free hand ridge splitting)
Number of subjects: 20
Study: 33691702

Group type: EXPERIMENTAL
Intervention: Supervised self-help PR maintenance program
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PR maintenance program
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control PR group without a maintenance program
Number of subjects: 144
Study: 32541548

Group type: EXPERIMENTAL
Intervention: Optimism training intervention
Number of subjects: 61
Study: 35691565

Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone (PMH) use
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Estrogen-only PMH use
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined estrogen-and-progesterone PMH use
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Younger age at menopause
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) use
Number of subjects: 27
Study: 33386201

Group type: EXPERIMENTAL
Intervention: Pilates exercise (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home exercise (group 2)
Number of subjects: 60
Study: 35092845

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR, 4.25 h of sleep/night)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal sleep duration (NS, 8.5 h of sleep/night)
Number of subjects: 16
Study: 34347860

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily
Number of subjects: 692

Group type: COMPARATOR
Intervention: Dupilumab 300 mg every other week
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 692

Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 692
Study: 35749144

Group type: EXPERIMENTAL
Intervention: Helichrysum italicum infusion (HI)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Helichrysum arenarium infusion (HA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 27
Study: 32332617

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (self-management of antihypertensive medication, self-measurement of blood pressure, hypocaloric and low sodium diet, and physical exercise)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Regular clinical practice (control group)
Number of subjects: 424
Study: 35773633

Group type: EXPERIMENTAL
Intervention: Continuous running exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Interval running exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise training (both continuous and interval running)
Number of subjects: 6
Study: 34418116

Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Arimoclomol (in subgroup receiving miglustat)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 32500599

Group type: EXPERIMENTAL
Intervention: Chitosan + 5% Dysphania ambrosioides (Group CA5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chitosan (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chitosan + 20% Dysphania ambrosioides (Group CA20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control-Blood clot (Group CO)
Number of subjects: 60
Study: 36158562

Group type: EXPERIMENTAL
Intervention: m-NMES-LT
Number of subjects: 21

Group type: COMPARATOR
Intervention: LT
Number of subjects: 21
Study: 33340513

Group type: EXPERIMENTAL
Intervention: Standing tutorial group (n = 41)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Standing tutorial group (n = 37)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sitting tutorial group (n = 36)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sitting tutorial group (n = 32)
Number of subjects: 96
Study: 34085115

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vonoprazan (10 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/day) with additional PPI (either esomeprazole or vonoprazan)
Number of subjects: 32
Study: 33504257

Group type: EXPERIMENTAL
Intervention: Autoregulatory CPP-targets (CPPopt55-15)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Fixed CPP-targets (CPP within 60-70 mm Hg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: CPP > 70 mm Hg
Number of subjects: 98
Study: 35775210

Group type: EXPERIMENTAL
Intervention: mHealth physical activity intervention
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Self-reported total PA
Number of subjects: 280

Group type: COMPARATOR
Intervention: Self-help (control) group
Number of subjects: 280
Study: 33764445

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 400 μg/m2/day for 5 days via intravenous infusion
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 88
Study: 35459108

Group type: EXPERIMENTAL
Intervention: Resistance exercise and nutritional optimization
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nutritional optimization only
Number of subjects: 112
Study: 33768619

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg twice daily for 24 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rifaximin 550 mg twice daily for 24 weeks
Number of subjects: 60
Study: 35798534

Group type: EXPERIMENTAL
Intervention: Ustekinumab (intravenous infusion 6 mg/kg at week 0, followed by subcutaneous injections of 90 mg at week 8 and every 8 weeks)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 516
Study: 34158031

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) applied to the vastus lateralis for 30 minutes (7s on, 7s off)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (quiet sitting for 30 minutes)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Number of subjects: 22
Study: 32829082

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the ON condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the OFF condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DBS in OCD ON condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DBS in OCD OFF condition
Number of subjects: 18
Study: 36041126

Group type: EXPERIMENTAL
Intervention: MSC suspension added to the graft (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Crestal approach (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Crestal approach (Group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lateral approach (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lateral approach (Group 1)
Number of subjects: 24
Study: 34335840

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (12 weeks, 5 times a week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aerobic exercise (12 weeks, 5 times a week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 70
Study: 33837986

Group type: EXPERIMENTAL
Intervention: Motor imagery training (20 minutes additional training)
Number of subjects: 32
Study: 32442026

Group type: EXPERIMENTAL
Intervention: Breastfeeding Education Program (BEP) using apron and Disaster Evacuation Baby Carrier (DEBC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 35943745

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.1 mg/kg)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2.0 μg/kg)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Normal saline (0.9%)
Number of subjects: 384
Study: 34385543

Group type: EXPERIMENTAL
Intervention: Durvalumab and pomalidomide combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durvalumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab plus pomalidomide with dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Durvalumab
Number of subjects: 0
Study: 32723399

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35863984

Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (sevoflurane or desflurane)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Propofol‐based total intravenous anesthesia (TIVA)
Number of subjects: 524
Study: 32684486

Group type: COMPARATOR
Intervention: Fish oil (FO, 6 g fish oil, 3.85 g EPA & DHA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coconut oil + fish oil (COFO, 18.65 g coconut oil, 15 g MCSFA + 6 g fish oil, 3.85 g EPA & DHA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coconut oil (CO, 18.65 g coconut oil, 15 g MCSFA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fish oil (FO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Coconut oil + fish oil (COFO)
Number of subjects: 15
Study: 33334564

Group type: EXPERIMENTAL
Intervention: Climate Schools-Combined intervention
Number of subjects: 6386

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6386
Study: 34952780

Group type: EXPERIMENTAL
Intervention: Gender-transformative life-skills education cum sports coaching program
Number of subjects: 853
Study: 34975377

Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS with wrist-ankle acupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: 5-Hz rTMS
Number of subjects: 25
Study: 34849603

Group type: EXPERIMENTAL
Intervention: Self-reported pain
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: US-modified CASPAR
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional CASPAR
Number of subjects: 126

Group type: COMPARATOR
Intervention: US-only criteria
Number of subjects: 126

Group type: COMPARATOR
Intervention: Screening questionnaires
Number of subjects: 126
Study: 34061883

Group type: EXPERIMENTAL
Intervention: Integrated treatment delivered by multidisciplinary teams at opioid agonist treatment clinics or community care centers, including on-site testing for HCV, liver fibrosis assessment, counseling, treatment, and posttreatment follow-up.
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard treatment delivered in hospital outpatient clinics.
Number of subjects: 298
Study: 35120873

Group type: EXPERIMENTAL
Intervention: Design A (distance zone [DZ] 1.5 mm / add 3.0 D)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Design B (DZ 1.5 mm / add 1.5 D)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Design C (DZ 3.0 mm / add 3.0 D)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Design D (DZ 3.0 mm / add 1.5 D)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All MFGPCL designs
Number of subjects: 17
Study: 34611040

Group type: EXPERIMENTAL
Intervention: Electronic differential diagnostic support (EDS) used early in the diagnostic process
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Electronic differential diagnostic support (EDS) used late in the diagnostic process
Number of subjects: 190
Study: 32872011

Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with acupressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure thunder-fire moxibustion
Number of subjects: 0
Study: 34590334

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ghrelin infusion (3 µg/kg loading dose followed by 16.9 ng/kg/min continuous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 34187120

Group type: EXPERIMENTAL
Intervention: FIFA 11+ program (12 weeks, 3 times/week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Regular training programs (Control)
Number of subjects: 59
Study: 33538417

Group type: EXPERIMENTAL
Intervention: Monitoring + reversal of neuromuscular blockade (M+R)
Number of subjects: 2084

Group type: COMPARATOR
Intervention: No monitoring nor reversal (noM+noR)
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Neostigmine reversal
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Sugammadex reversal
Number of subjects: 2084
Study: 32199243

Group type: EXPERIMENTAL
Intervention: Digital Learning Materials (DLMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 0